Tensive and the EIC Accelerator: Breast Tissue That Regrows

Tensive, a Milan company led by CEO Sanjay Kakkar, makes REGENERA, a porous, resorbable scaffold that surgeons place during a lumpectomy so the patient's own tissue can grow into the gap left by the tumour. Its EIC project described "a resorbable implant designed to restore a natural breast through tissue self-regeneration", made of a biocompatible polymer, meant to avoid follow-up surgery and the risks of silicone implants and fat grafting, according to CORDIS.

The European Innovation Council granted €2,498,600 towards a €3.57 million project from March 2023 to February 2025. The final report says the pivotal clinical trial was approved in all countries involved, six extra centres were added to speed enrolment, and the study "has been concluded with positive results". Documentation for CE marking as a Class III device was prepared. But purification equipment was postponed "due to a change of the company strategy to accelerate the CE mark", and a new manufacturing facility was pushed back to 2026. In September 2026 Tensive signed a convertible loan of up to €20 million with the European Investment Bank and said it expects EU approval "as soon as early 2027".

Where Tensive Stands Now

In July 2026 Tensive reported 12-month data from the pivotal trial covering all 94 patients: 87 had passed 12 months and 30 had completed 24 months, 94.2% of evaluable cases had good-to-excellent cosmetic results, and the implant did not interfere with cancer imaging, the EIB announcement summarises. Interim six-month results were published in the journal Updates in Surgery in April 2026. The EIB loan covers half of a €40 million plan to reach CE marking, scale up manufacturing and launch in Europe; Tensive is seeking the rest from equity investors and partners.

The Technology: A Scaffold That Disappears

After a lumpectomy, some women are left with deformity when the tumour is large relative to the breast. Tensive's scaffold is placed during the same operation and is gradually replaced by the patient's own tissue. Five-year follow-up from its first-in-human study shows persistent volume, blood vessel growth and gradual resorption without capsule formation, the company says. Tensive estimates that 1.6 million women a year lack viable reconstruction options after lumpectomy.

What the EIC Project Promised, and What CORDIS Shows

The project covered manufacturing, the tests needed for commercialisation, the pivotal trial and market preparation. The trial and testing were done and the CE file was prepared. Manufacturing scale-up was deferred to reach CE marking faster, and CE approval itself had not been granted by September 2026. An FDA pre-submission was started for a Class II route in the US. CORDIS lists the project as closed.

1. Pivotal clinical trialDeliveredPositive, per company.
2. CE mark fileDeliveredPrepared.
3. Manufacturing scale-upDeferredFacility to 2026.
4. CE approvalNot yetExpected 2027.

The Money

Tensive closed a €14 million Series A in January 2025, led by Panakès Partners with the EIC Fund, CDP and Recomec, according to its announcement. The EIB loan, backed by InvestEU, is drawable in tranches of €8 million and €12 million subject to conditions. The EIC Fund's stake and Tensive's cash position are not public.

What Cannot Be Checked

Why Europe Should Care

Breast-conserving surgery is standard for early breast cancer, but reconstruction options after lumpectomy are limited. A resorbable implant made in Italy could fill that gap. EU money now supports Tensive through the EIC grant, the EIC Fund and the EIB; the product still has to clear approval and reach surgeons.

The Verdict

Tensive and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.